<DOC>
	<DOCNO>NCT00530179</DOCNO>
	<brief_summary>The purpose study evaluate : 1. whether image test call PET ( Positron emission tomography ) scan perform two cycle standard chemotherapy able identify patient high cure rate complete standard chemotherapy alone ; 2. whether high dose chemotherapy ( HDCT ) autologous stem cell transplantation ( ASCT ) use combination antibody call Rituximab result high cure rate patient predict poorly standard chemotherapy PET scan .</brief_summary>
	<brief_title>FDG-PET-Stratified R-DICEP R-Beam/ASCT For Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Age 1865 year Diagnosis Diffuse Large BCell Lymphoma Adverse Prognosis = Stage 3 4 elevate LDH No one prior cycle RCHOP chemotherapy Adequate cardiac function No central nervous system involvement lymphoma Histological diagnosis Diffuse Large Bcell Lymphoma Pregnant lactate female Use anticancer therapy Other serious illness would compromise study participation Prior malignancy Prior stem cell transplant radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>CHOP Chemotherapy protocol</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Fluorodeoxyglucose F18</keyword>
</DOC>